Curr Opin Pulm Med 2021 Jun 9. Epub 2021 Jun 9.
Department of Medicine, University of Alberta, Clinical Sciences Building, Edmonton, Alberta Department of Medicine, Division of Hematology, Ottawa Research Hospital Institute Department of Medicine, University of Ottawa, The Ottawa Research Hospital Institute, The Ottawa Hospital General Campus, Ottawa, Ontario, Canada.
Purpose Of Review: The pivotal phase III trials demonstrating efficacy and safety of direct oral anticoagulants (DOACs) in the treatment of venous thromboembolism (VTE) or nonvalvular atrial fibrillation (NVAF) excluded patients with important and common comorbidities, including obesity, advanced chronic kidney disease, cirrhosis, cancer and antiphospholipid antibody syndrome. Despite the lack of large prospective randomized control trials in these patient populations, the use of DOACs has led to a wealth of efficacy and safety data within these groups.
Recent Findings: Retrospective studies, meta-analyses, national databases and pharmacokinetic data have shed light on the efficacy and safety of DOACs in these patient populations. Read More